Literature DB >> 22019328

Impact of lung transplantation on serum lipids in COPD.

Robert M Reed1, Salman Hashmi, Michael Eberlein, Aldo Iacono, Giora Netzer, Andrew DeFilippis, Reda E Girgis, Peter P Toth, Steven Scharf, Steven Jones.   

Abstract

BACKGROUND: Severe chronic obstructive pulmonary disease is associated with high HDL cholesterol (HDL-C). We sought to examine the effect of lung transplantation on lipid profiles in patients with COPD.
METHODS: We analyzed 101 lung transplant recipients in a retrospective cohort of patients from two centers in whom lipid values were available both before as well as after transplantation. Sixty-one subjects were transplanted for severe COPD (93% GOLD stage 4).
RESULTS: Eighty-nine percent of subjects with COPD exhibited a decline in HDL-C. Median decline for the COPD cohort was 25 mg/dL (IQR 12-38 mg/dL, p < 0.0001). Non-COPD subjects exhibited no significant changes in HDL-C. Other lipid changes in the COPD cohort included a rise in triglycerides of 70 mg/dL (IQR 35 to 140, p < 0.0001). Decreases in HDL-C levels were independent from the rise in triglyceride levels. Neither LDL-C nor non-HDL-C demonstrated significant changes. Subjects with greater increases in prednisone exposure post-transplant exhibited lesser declines in HDL-C. Compared with tacrolimus, cyclosporine had no effect on observed changes in HDL-C or triglycerides, but was associated with a greater median rise in LDL-C.
CONCLUSIONS: In patients with COPD, lung transplantation results in reductions in the serum levels of HDL-C. These changes are not observed in patients undergoing lung transplantation for diagnoses other than COPD.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22019328     DOI: 10.1016/j.rmed.2011.10.003

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  8 in total

Review 1.  Post-transplant dyslipidemia: Mechanisms, diagnosis and management.

Authors:  Arnav Agarwal; G V Ramesh Prasad
Journal:  World J Transplant       Date:  2016-03-24

2.  Clinical significance of serum lipids in idiopathic pulmonary alveolar proteinosis.

Authors:  Cun S Fang; Ying C Wang; Tao H Zhang; Jing Wu; Wei Wang; Chun Wang; Ming Y Zhang
Journal:  Lipids Health Dis       Date:  2012-01-17       Impact factor: 3.876

3.  APOM and high-density lipoprotein cholesterol are associated with lung function and per cent emphysema.

Authors:  Kristin M Burkart; Ani Manichaikul; Jemma B Wilk; Firas S Ahmed; Gregory L Burke; Paul Enright; Nadia N Hansel; Demondes Haynes; Susan R Heckbert; Eric A Hoffman; Joel D Kaufman; Jun Kurai; Laura Loehr; Stephanie J London; Yang Meng; George T O'Connor; Elizabeth Oelsner; Marcy Petrini; Tess D Pottinger; Charles A Powell; Susan Redline; Jerome I Rotter; Lewis J Smith; María Soler Artigas; Martin D Tobin; Michael Y Tsai; Karol Watson; Wendy White; Taylor R Young; Stephen S Rich; R Graham Barr
Journal:  Eur Respir J       Date:  2013-07-30       Impact factor: 16.671

4.  Tobacco Smoke Exposure Reduces Paraoxonase Activity in a Murine Model.

Authors:  Robert M Reed; Saif M Borgan; Michael Eberlein; Monica Goldklang; Joshua Lewis; Michael Miller; Mohamad Navab; Bo S Kim
Journal:  Int J Biomed Sci       Date:  2017-03

Review 5.  Nutritional Requirements of Lung Transplant Recipients: Challenges and Considerations.

Authors:  Valerie Jomphe; Larry C Lands; Genevieve Mailhot
Journal:  Nutrients       Date:  2018-06-19       Impact factor: 5.717

Review 6.  High-Density Lipoproteins: A Role in Inflammation in COPD.

Authors:  Stanislav Kotlyarov
Journal:  Int J Mol Sci       Date:  2022-07-23       Impact factor: 6.208

7.  Pretransplant dyslipidaemia determines outcome in lung transplant recipients.

Authors:  Urs Wenger; Silvia R Cottini; Georg Noll; Stefan Arndt; Paul A Stehberger; Stefanie Klinzing; Reto A Schuepbach; Markus Béchir
Journal:  Lipids Health Dis       Date:  2013-04-23       Impact factor: 3.876

Review 8.  Participation of ABCA1 Transporter in Pathogenesis of Chronic Obstructive Pulmonary Disease.

Authors:  Stanislav Kotlyarov
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.